glp-1 agonists cancer risk of pancreatic associated with receptor agonist therapy Forest plot of GLP-1 receptor

I 2 = 0%), or vomiting (OR: 8.22, 95% CI: 4.02, 16.81

Each GLP-1RA has explicit indications and contraindications for weight loss [Reference Pratley, Kang, Trautmann, Hompesch, Han and Stewart49]

We earn revenue from product sales linked in this article

The obesity drug pipeline remains robust, with next-generation therapies and novel mechanisms progressing through multiple phases of clinical development

Starting July 2026, all formulations of Foundayo are covered under the GLP-1 Bridge program at a $50/month copay

Several additional GLP-1 receptor agonists also display neuroprotective properties in preclinical AD models